BACKGROUND: In the Balearic Islands, as in other areas of the Mediterranean basin, there is a significant proportion of asymptomatic Leishmania (L.) infantum-infected blood donors, who may represent an important threat to transfusion safety. The Balearic Islands blood bank, located in an area endemic for L. infantum, carried out a study of donors and patients to investigate the impact of this infectious disease on blood safety in the region. MATERIALS AND METHODS: Twenty asymptomatic Leishmania-infected blood donors were followed-up between 2008 and 2011 to investigate the evolution of Leishmania infection in asymptomatic carriers. Their blood was periodically tested for anti-Leishmania antibodies by western blot and for Leishmania DNA by quantitative polymerase chain reaction (qPCR). Additionally, the prevalence of L. infantum infection was investigated in a group of 68 multiply transfused patients to ascertain the risk of transfusion-transmitted leishmaniasis (TTL) in the region, taking into account regular blood component production practices such as pre-storage leucodepletion and pathogen reduction technology. RESULTS: All 20 donors remained asymptomatic over the study period (2008-2011). Most donors had repeatedly positive qPCR results, either persistently or intermittently, but showed no symptoms of Leishmaniasis. Levels of parasitaemia were remarkably low in asymptomatic donors, with values ≤1 parasite/mL. Despite multiple transfusions received over 15 years, no transfused patient studied was infected with L. infantum. DISCUSSION: L. infantum-infected donors can remain asymptomatic for at least 3 years. In our region, no cases of TTL were detected, despite an active search in multiply transfused patients. This seems to be related to two independent variables: (i) a low concentration of the parasite in the peripheral blood of asymptomatic carriers and (ii) the application of methods with proven efficacy against TTL, such as leucodepletion and pathogen reduction technology.
BACKGROUND: In the Balearic Islands, as in other areas of the Mediterranean basin, there is a significant proportion of asymptomatic Leishmania (L.) infantum-infected blood donors, who may represent an important threat to transfusion safety. The Balearic Islands blood bank, located in an area endemic for L. infantum, carried out a study of donors and patients to investigate the impact of this infectious disease on blood safety in the region. MATERIALS AND METHODS: Twenty asymptomatic Leishmania-infected blood donors were followed-up between 2008 and 2011 to investigate the evolution of Leishmania infection in asymptomatic carriers. Their blood was periodically tested for anti-Leishmania antibodies by western blot and for Leishmania DNA by quantitative polymerase chain reaction (qPCR). Additionally, the prevalence of L. infantum infection was investigated in a group of 68 multiply transfused patients to ascertain the risk of transfusion-transmitted leishmaniasis (TTL) in the region, taking into account regular blood component production practices such as pre-storage leucodepletion and pathogen reduction technology. RESULTS: All 20 donors remained asymptomatic over the study period (2008-2011). Most donors had repeatedly positive qPCR results, either persistently or intermittently, but showed no symptoms of Leishmaniasis. Levels of parasitaemia were remarkably low in asymptomatic donors, with values ≤1 parasite/mL. Despite multiple transfusions received over 15 years, no transfused patient studied was infected with L. infantum. DISCUSSION: L. infantum-infected donors can remain asymptomatic for at least 3 years. In our region, no cases of TTL were detected, despite an active search in multiply transfused patients. This seems to be related to two independent variables: (i) a low concentration of the parasite in the peripheral blood of asymptomatic carriers and (ii) the application of methods with proven efficacy against TTL, such as leucodepletion and pathogen reduction technology.
Authors: L J Cardo; F J Rentas; L Ketchum; J Salata; R Harman; W Melvin; P J Weina; J Mendez; H Reddy; R Goodrich Journal: Vox Sang Date: 2006-02 Impact factor: 2.144
Authors: Richard T Eastman; Lynn K Barrett; Kent Dupuis; Frederick S Buckner; Wesley C Van Voorhis Journal: Transfusion Date: 2005-09 Impact factor: 3.157
Authors: Manuela Sales Lima Nascimento; Vanessa Carregaro; Djalma Souza Lima-Júnior; Diego Luís Costa; Bernhard Ryffel; Malcolm S Duthie; Amélia de Jesus; Roque Pacheco de Almeida; João Santana da Silva Journal: J Infect Dis Date: 2014-10-01 Impact factor: 5.226
Authors: Charles Mary; Françoise Faraut; Marie-Pierre Drogoul; Bernard Xeridat; Nicolas Schleinitz; Bernadette Cuisenier; Henri Dumon Journal: Am J Trop Med Hyg Date: 2006-11 Impact factor: 2.345
Authors: D S Kyriakou; M G Alexandrakis; F H Passam; T V Kourelis; P Foundouli; E Matalliotakis; A N Maniatis Journal: Transfus Med Date: 2003-04 Impact factor: 2.019
Authors: G Martín-Ezquerra; R Fisa; C Riera; V Rocamora; A Fernández-Casado; C Barranco; T Serra; T Baró; R M Pujol Journal: Br J Dermatol Date: 2009-06-04 Impact factor: 9.302
Authors: Edwin Kniha; Julia Walochnik; Wolfgang Poeppl; Gerhard Mooseder; Adelheid G Obwaller Journal: Wien Klin Wochenschr Date: 2020-01-07 Impact factor: 1.704